XML 48 R24.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Other (Income) Expense, Net | 12 Months Ended
--- | ---
Dec. 31, 2018
Other Income and Expenses [Abstract] |
Other (Income) Expense, Net | Other (Income) Expense, Net Other (income) expense, net, consisted of:
Years Ended December 31 | 2018 |  | 2017 |  | 2016
Interest income | $ | (343 | ) |  | $ | (385 | ) |  | $ | (328 | )
Interest expense | 772 |  |  | 754 |  |  | 693 |
Exchange losses (gains) | 145 |  |  | (11 | ) |  | 174 |
Income on investments in equity securities, net (1) | (324 | ) |  | (352 | ) |  | (43 | )
Net periodic defined benefit plan (credit) cost other than service cost | (512 | ) |  | (512 | ) |  | (531 | )
Other, net | (140 | ) |  | 6 |  |  | 224 |
| $ | (402 | ) |  | $ | (500 | ) |  | $ | 189 |
(1) Includes net realized and unrealized gains and losses on investments in equity securities either owned directly or through ownership interests in investment funds. Income on investments in equity securities, net, in 2018 reflects the recognition of unrealized net gains pursuant to the prospective adoption of ASU 2016-01 on January 1, 2018 (see Note 2). The increase in income on investments in equity securities, net, in 2017 was driven primarily by higher realized gains on sales. Other, net (as presented in the table above) in 2018 includes a gain of $115 million related to the settlement of certain patent litigation (see Note 11), income of $99 million related to AstraZeneca’s option exercise (see Note 9), and a gain of $85 million resulting from the receipt of a milestone payment for an out-licensed migraine clinical development program. Other, net in 2018 also includes $144 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8), as well as $41 million of charges related to the write-down of assets held for sale to fair value in anticipation of the dissolution of the Company’s joint venture with Supera Farma Laboratorios S.A. in Brazil. Other, net in 2017 includes income of $232 million related to AstraZeneca’s option exercise and a $191 million loss on extinguishment of debt (see Note 10). Other, net in 2016 includes a charge of $625 million related to the previously disclosed settlement of worldwide patent litigation related to Keytruda, a gain of $117 million related to the settlement of other patent litigation, gains of $100 million resulting from the receipt of milestone payments for out-licensed migraine clinical development programs, and $98 million of income related to AstraZeneca’s option exercise. Interest paid was $777 million in 2018, $723 million in 2017 and $686 million in 2016.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI http://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI http://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration